tiprankstipranks
Advertisement
Advertisement

CVKD Stock Latest News

Cadrenal Therapeutics Launches Cardiac Acute Care Franchise Strategy
Company AnnouncementsCadrenal Therapeutics Launches Cardiac Acute Care Franchise Strategy
9d ago
8K
CVKD
Cadrenal Therapeutics Announces Chief Medical Officer Transition
PremiumCompany Announcements
Cadrenal Therapeutics Announces Chief Medical Officer Transition
13d ago
8K
CVKD
Cadrenal Therapeutics files to sell 2.94M shares of common stock for holders
PremiumThe Fly
Cadrenal Therapeutics files to sell 2.94M shares of common stock for holders
17d ago
CVKD
Cadrenal Therapeutics announces clinical data from CAD-1005 study
PremiumThe Fly
Cadrenal Therapeutics announces clinical data from CAD-1005 study
17d ago
CVKD
Cadrenal Therapeutics Announces Chief Medical Officer Resignation
PremiumCompany Announcements
Cadrenal Therapeutics Announces Chief Medical Officer Resignation
20d ago
8K
CVKD
Cadrenal Therapeutics Secures Private Placement to Extend Runway
PremiumCompany AnnouncementsCadrenal Therapeutics Secures Private Placement to Extend Runway
29d ago
8K
CVKD
Cadrenal Names Interim CFO, Realigns Board Structure
Premium
Company Announcements
Cadrenal Names Interim CFO, Realigns Board Structure
1M ago
8K
CVKD
Cadrenal Pursues Rare Pediatric Designation for Tecarfarin
Premium
Company Announcements
Cadrenal Pursues Rare Pediatric Designation for Tecarfarin
1M ago
8K
CVKD
Cadrenal Therapeutics to file for FDA RPDD for tecarfarin in Kawasaki Disease
PremiumThe Fly
Cadrenal Therapeutics to file for FDA RPDD for tecarfarin in Kawasaki Disease
1M ago
CVKD
Cadrenal Therapeutics to initiate CAD-1005 trial
PremiumThe Fly
Cadrenal Therapeutics to initiate CAD-1005 trial
1M ago
CVKD
Cadrenal Therapeutics Announces CFO Transition and Interim Appointment
PremiumCompany Announcements
Cadrenal Therapeutics Announces CFO Transition and Interim Appointment
2M ago
8K
CVKD
Cadrenal Therapeutics completes CAD-1005 End-of-Phase 2 meeting with FDA
PremiumThe Fly
Cadrenal Therapeutics completes CAD-1005 End-of-Phase 2 meeting with FDA
3M ago
CVKD
Cadrenal Advances CAD-1005 Into FDA-Guided Phase 3 Trial
PremiumCompany AnnouncementsCadrenal Advances CAD-1005 Into FDA-Guided Phase 3 Trial
3M ago
8K
CVKD
Cadrenal Therapeutics files to sell 1.18M shares of common stock for holders
Premium
The Fly
Cadrenal Therapeutics files to sell 1.18M shares of common stock for holders
3M ago
CVKD
Cadrenal Therapeutics price target lowered to $13 from $32 at H.C. Wainwright
Premium
The Fly
Cadrenal Therapeutics price target lowered to $13 from $32 at H.C. Wainwright
4M ago
CVKD
Cadrenal Therapeutics Inc trading halted, volatility trading pause
PremiumThe Fly
Cadrenal Therapeutics Inc trading halted, volatility trading pause
4M ago
CVKD
Cadrenal Therapeutics Inc trading resumes
PremiumThe Fly
Cadrenal Therapeutics Inc trading resumes
4M ago
CVKD
Cadrenal Therapeutics Enters Warrant Inducement Financing Agreement
PremiumCompany Announcements
Cadrenal Therapeutics Enters Warrant Inducement Financing Agreement
4M ago
8K
CVKD
FDA Review Uncertainty Puts Cadrenal Therapeutics’ CAD-1005 Phase 3 Timeline and Costs at Risk
PremiumCompany Announcements
FDA Review Uncertainty Puts Cadrenal Therapeutics’ CAD-1005 Phase 3 Timeline and Costs at Risk
4M ago
CVKD
Cadrenal Therapeutics, Inc. (CVKD) Q4 Earnings Cheat Sheet
PremiumPre-EarningsCadrenal Therapeutics, Inc. (CVKD) Q4 Earnings Cheat Sheet
5M ago
CVKD
Cadrenal Highlights CAD-1005 Preclinical Data in Metabolic Disease
Premium
Company Announcements
Cadrenal Highlights CAD-1005 Preclinical Data in Metabolic Disease
5M ago
8K
CVKD
Cadrenal Therapeutics highlights research on 12-LOX inhibition
Premium
The Fly
Cadrenal Therapeutics highlights research on 12-LOX inhibition
5M ago
CVKD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >